Innovative Health Technology Clients Appoint Instinctif Partners to Provide Communications Counsel
6 October 2014, London, Manchester, Munich, Boston, Sydney, Melbourne: In the third quarter of 2014, the Life Sciences team of international business communications consultancy, Instinctif Partners, won five new retainer mandates, as well as securing three new project clients.
Retainers include Financial PR to add to the Corporate PR for Premaitha Health, won last quarter, and Corporate PR for DNA Electronics, IR/Corporate PR for Mucosis, and Corporate PR for Vascular Flow Technologies.
London-based private company DNA Electronics is using its next generation semiconductor DNA sequencing technology in a point-of-need USB-sized diagnostics device to detect and help direct the right treatment of infectious diseases, with an initial focus on sepsis.
Mucosis, a clinical stage private Dutch biotechnology company is developing innovative mucosal vaccines for infectious diseases that can be applied needle-free via the nose or mouth. It returns to the fold after a project in 2012 in a mandate shared with US based Lazar Partners.
LSE-listed NetScientific is based in Cambridge, UK and New York, US and is focused on commercializing transformative biomedical and healthcare technologies and investing in late-stage translational research projects.
Vascular Flow Technologies, based in Dundee, Scotland is a private developer of a technology that improves the life of vascular grafts and the disease progression associated with them.
The project clients include:
HealthUnlocked, the social network for health, enables people to find others with similar health backgrounds to take on health concerns together. The London-based company brought in the Instinctif Partners team to support a PR project and provide messaging advice.
Celenys, a private French biotechnology company that specializes in developing innovative 3D in vitro study models to come closer to in vivo systems by mimicking the cellular microenvironment, signed up Instinctif Partners for an ad hoc consultancy project.
Bionic Vision, based on a Melbourne University research program, has engaged the Australian team and our US partner, Lazar Partners, to provide media outreach around a conference. Bionic Vision is developing electronic-implants to create a bionic eye giving new sight to people blinded by retinitis pigmentosa.
Sue Charles, Managing Partner, Instinctif Partners Life Sciences, commented “There is so much exciting innovation out there that has the potential to make a major impact on healthcare in the future. Our new clients have a wide breadth and scope of technology and I know our team can make a valuable contribution to bringing them to the attention of target audiences and helping them to achieve their business goals.”
For further information:
Managing Partner, Life Sciences
+44 (0)20 7457 2020
back to news